Tirzepatide
GIP/GLP-1 · s.c. · Eli Lilly
Summary
- Also known as
- Zepbound / Mounjaro
- Mechanism
- GIP/GLP-1
- Route
- s.c.
- Company
- Eli Lilly
- Highest development stage
- approved
- Status (as of data cut)
- Approved: obesity, T2D, obstructive sleep apnoea (FDA); MACE reduction added to the Mounjaro US label (2026) verify
- Next milestone
- HFpEF (SUMMIT) and MMO outcomes
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 4 approved / in label | FDA: Zepbound; EMA: Mounjaro (weight management) | Zepbound US label (2026) |
| T2D | 4 approved / in label | FDA and EMA: Mounjaro | Mounjaro EPAR |
| CV outcomes | 4 approved / in label | FDA label (Mounjaro, 2026): MACE reduction in T2D at high CV risk, based on SURPASS-CVOT | SURPASS-CVOT |
| CKD | 1 phase 2 / signal | Phase 2 kidney study and kidney secondary analyses of SURPASS-CVOT; no dedicated phase 3 | SURPASS-CVOT kidney analysis |
| HFpEF | 3 positive phase 3 | Positive phase 3 (CV death or worsening HF); EU label cites results in section 5.1, not as an indication | SUMMIT |
| MASH | 2 phase 3 ongoing | Phase 2 positive (SYNERGY-NASH); phase 3 ongoing | SYNERGY-NASH (phase 2) |
| Sleep apnoea | 4 approved / in label | FDA: Zepbound for moderate-to-severe OSA in adults with obesity | SURMOUNT-OSA |
| Knee OA | 2 phase 3 ongoing | Phase 3 ongoing | |
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
US prescribing information: indications
Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.
MOUNJARO US label 29.07.2026
1 INDICATIONS AND USAGE MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 )
Zepbound US label 28.08.2026
1 INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ( 1 ) Limitations of Use: Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.
Mounjaro US label 27.08.2026
1 INDICATIONS AND USAGE MOUNJARO ® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 ) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EloraTZP phase 2b (obesity + T2D) | tirzepatide 15 mg | t2d | 48 | — | −14.8 % vs −3.0 % Δ −11.8 pp | — | −2.4 vs −0.3 | 2.9 vs 16.7 | — | — | — | — | — | press release |
| SURMOUNT-1 | tirzepatide 5 mg | obesity | 72 | 2539 | −16.0 % vs −2.4 % Δ −13.6 pp | −15.0 % vs −3.1 % Δ −11.9 pp | — | 4.3 vs 2.6 | — | 24.6 vs 9.5 | 8.3 vs 1.7 | 6.3 vs 6.8 | — | verified |
| SURMOUNT-1 | tirzepatide 10 mg | obesity | 72 | 2539 | −21.4 % vs −2.4 % Δ −19.0 pp | −19.5 % vs −3.1 % Δ −16.4 pp | — | 7.1 vs 2.6 | — | 33.3 vs 9.5 | 10.7 vs 1.7 | 6.9 vs 6.8 | — | verified |
| SURMOUNT-1 | tirzepatide 15 mg | obesity | 72 | 2539 | −22.5 % vs −2.4 % Δ −20.1 pp | −20.9 % vs −3.1 % Δ −17.8 pp | — | 6.2 vs 2.6 | — | 31.0 vs 9.5 | 12.2 vs 1.7 | 5.1 vs 6.8 | — | verified |
| SURMOUNT-2 | tirzepatide 15 mg | t2d | 72 | 938 | −15.7 % vs −3.3 % Δ −12.4 pp | −14.7 % vs −3.2 % Δ −11.5 pp | −2.1 vs −0.5 | 7.4 vs 3.8 | 13.8 vs 14.9 | 21.9 vs 6.3 | 13.2 vs 3.2 | 8.7 vs 7.3 | — | verified |
| SURMOUNT-2 | tirzepatide 10 mg | t2d | 72 | 938 | −13.4 % vs −3.3 % Δ −10.1 pp | −12.8 % vs −3.2 % Δ −9.6 pp | −2.1 vs −0.5 | 3.8 vs 3.8 | 9.3 vs 14.9 | 20.2 vs 6.3 | 10.9 vs 3.2 | 5.8 vs 7.3 | — | verified |
| SURMOUNT-5 (head-to-head) | tirzepatide 10/15 mg vs semaglutide 2.4 mg: −13.7 %; treatment discontinuation 21.3 % | obesity | 72 | 751 | −21.6 % | −20.2 % | — | 6.1 | 18.4 | 43.6 | 15.0 | 4.8 | −10.2 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- tirzepatide 5 mg: Per-arm discontinuation of the study drug is printed only as a range across doses.
- tirzepatide 10 mg: Per-arm discontinuation of the study drug is printed only as a range across doses.
- tirzepatide 15 mg: Per-arm discontinuation of the study drug is printed only as a range across doses.
Verbatim quotes from the source (39)
- tirzepatide 5 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
−16.0% (95% CI, −16.8 to −15.2), a weight reduction of 16.1 kg (35.5 lb), with the 5-mg dose
- tirzepatide 5 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
−15.0% (95% CI, −15.9 to −14.2) with a 5-mg weekly dose of tirzepatide
- tirzepatide 5 mg · ae_dc · Results, Participants; Table 4 (27 [4.3])
Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
- tirzepatide 5 mg · nausea · Table 4, adverse events in at least 5% of participants
Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
- tirzepatide 5 mg · vomiting · Table 4, adverse events in at least 5% of participants
Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
- tirzepatide 5 mg · sae · Table 4
Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
- tirzepatide 10 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
−21.4% (95% CI, −22.2 to −20.6), a reduction of 22.2 kg (48.9 lb), with the 10-mg dose
- tirzepatide 10 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
−19.5% (95% CI, −20.4 to −18.5) with a 10-mg dose
- tirzepatide 10 mg · ae_dc · Results, Participants; Table 4 (45 [7.1])
Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
- tirzepatide 10 mg · nausea · Table 4, adverse events in at least 5% of participants
Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
- tirzepatide 10 mg · vomiting · Table 4, adverse events in at least 5% of participants
Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
- tirzepatide 10 mg · sae · Table 4
Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
- tirzepatide 15 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
−22.5% (95% CI, −23.3 to −21.7), a reduction of 23.6 kg (52.0 lb) with the 15-mg dose
- tirzepatide 15 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
−20.9% (95% CI, −21.8 to −19.9) with a 15-mg dose
- tirzepatide 15 mg · ae_dc · Results, Participants; Table 4 (39 [6.2])
Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
- tirzepatide 15 mg · nausea · Table 4, adverse events in at least 5% of participants
Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
- tirzepatide 15 mg · vomiting · Table 4, adverse events in at least 5% of participants
Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
- tirzepatide 15 mg · sae · Table 4
Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
- tirzepatide 15 mg · nausea · Table 3
| Nausea | 63 (20·2) | 68 (21·9) | 20 (6·3) |
- tirzepatide 15 mg · vomiting · Table 3
| Vomiting | 34 (10·9) | 41 (13·2) | 10 (3·2) |
- tirzepatide 15 mg · disc_any · Figure 1 (trial profile)
| 29 (9·3%) discontinued study treatment | 43 (13·8%) discontinued study treatment | 47 (14·9%) discontinued study treatment |
- tirzepatide 15 mg · sae · Table 3
| Serious adverse events\* | 18 (5·8) | 27 (8·7) | 23 (7·3) |
- tirzepatide 15 mg · ae_dc · Table 3 (columns: 10 mg, 15 mg, placebo)
| Adverse events leading to discontinuation of study drug† | 12 (3·8) | 23 (7·4) | 12 (3·8) |
- tirzepatide 15 mg · hba1c · Table 2 + Results
| Change in HbA₁c, % | -2·07 (0·06) | -2·08 (0·07) | -0·51 (0·07) | ETD -1·55 (-1·74, -1·37); p<0·0001 | ETD -1·57 (-1·76, -1·37); p<0·0001 |
- tirzepatide 10 mg · nausea · Table 3
| Nausea | 63 (20·2) | 68 (21·9) | 20 (6·3) |
- tirzepatide 10 mg · vomiting · Table 3
| Vomiting | 34 (10·9) | 41 (13·2) | 10 (3·2) |
- tirzepatide 10 mg · disc_any · Figure 1 (trial profile)
| 29 (9·3%) discontinued study treatment | 43 (13·8%) discontinued study treatment | 47 (14·9%) discontinued study treatment |
- tirzepatide 10 mg · sae · Table 3
| Serious adverse events\* | 18 (5·8) | 27 (8·7) | 23 (7·3) |
- tirzepatide 10 mg · ae_dc · Table 3 (columns: 10 mg, 15 mg, placebo)
| Adverse events leading to discontinuation of study drug† | 12 (3·8) | 23 (7·4) | 12 (3·8) |
- tirzepatide 10/15 mg · weight_eff · Figure 2A (efficacy estimand, week 72; text-extracted end-po
−15.4 −21.6
- tirzepatide 10/15 mg · weight_tp · Results, Change in Body Weight; Table 2
The least-squares mean percent change in body weight from baseline to week 72 was −20.2% with tirzepatide (95% confidence interval [CI], −21.4 to −19.1)
- tirzepatide 10/15 mg · ae_dc · Table 3
Discontinuation of the trial treatment because of adverse events 23 (6.1)
- tirzepatide 10/15 mg · nausea · Table 3
Nausea 163 (43.6)
- tirzepatide 10/15 mg · vomiting · Table 3
Vomiting 56 (15.0)
- tirzepatide 10/15 mg · sae · Table 3
Serious adverse events 18 (4.8)
- tirzepatide 10/15 mg · sbp · Results, Change in Waist Circumference and Cardiometabolic R
Systolic blood pressure showed improvements with tirzepatide (least-squares mean change, −10.2 mm Hg; 95% CI, −11.4 to −8.9)
- tirzepatide 10/15 mg · disc_any · Results, Participants (computed 100−81.6)
80.2% completed the 72 weeks of trial treatment (81.6% in the tirzepatide group and 78.7% in the semaglutide group)
- tirzepatide 15 mg · weight_eff · press release
tirzepatide 15 mg reduced body weight by an average of 34.4 lbs (14.8%
- tirzepatide 15 mg · ae_dc · press release, safety paragraph
Treatment discontinuation rates due to adverse events were 10.8% to 27.0% with EloraTZP, 0% to 10.8% with eloralintide, 2.9% with tirzepatide and 16.7% with placebo.
Outcome trials
Cardiovascular and kidney outcome trials
SURPASS-CVOT tirzepatide 5–15 mg vs dulaglutide 1.5 mg (active) · T2D + established ASCVD · n = 13299 · 2025 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE (vs dulaglutide) primary Composite of death from cardiovascular causes, myocardial infarction, or stroke (95.3% CI reported, adjusted for interim analysis) | 0.92 | 0.83–1.01 | 801 vs 862 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.89 | 0.77–1.02 | 367 vs 408 | verified |
| All-cause death Death from any cause | 0.84 | 0.75–0.94 | 566 vs 669 | verified |
| Myocardial infarction Myocardial infarction (the text does not specify fatal or non-fatal; component of primary composite) | 0.86 | 0.74–1.00 | 311 vs 357 | verified |
| Stroke Stroke (the text does not specify fatal or non-fatal; component of primary composite) | 0.91 | 0.76–1.09 | 229 vs 249 | verified |
| CV death or worsening HF Composite of death from cardiovascular causes or hospitalization or urgent visit for heart failure | 0.91 | 0.81–1.03 | 512 vs 557 | verified |
| Expanded MACE (MACE + revasc.) 4-point composite: death from CV causes, myocardial infarction, stroke, or coronary revascularization (secondary end point); comparator dulaglutide 1.5 mg (active control) | 0.88 | 0.81–0.96 | 1089 vs 1217 | verified |
Verbatim quotes (7)
- 3-point MACE (vs dulaglutide) · Abstract; Results, paragraph 1; Table 2
A primary end-point event occurred in 801 patients (12.2%) in the tirzepatide group and 862 (13.1%) in the dulaglutide group (hazard ratio, 0.92; 95.3% confidence interval, 0.83 to 1.01
- Cardiovascular death · Results, paragraph 1; Table 2
Death from cardiovascular causes occurred in 367 patients (5.6%) in the tirzepatide group and 408 (6.2%) in the dulaglutide group (hazard ratio, 0.89; 95% CI, 0.77 to 1.02).
- All-cause death · Results, paragraph 1; Table 2
Death from any cause occurred in 566 patients (8.6%) in the tirzepatide group and 669 (10.2%) in the dulaglutide group (hazard ratio, 0.84; 95% CI, 0.75 to 0.94)
- Myocardial infarction · Results, paragraph 1; Table 2
Myocardial infarction occurred in 311 patients (4.7%) and 357 patients (5.4%), respectively (hazard ratio, 0.86; 95% CI, 0.74 to 1.00).
- Stroke · Results, paragraph 1; Table 2
Stroke occurred in 229 patients (3.5%) and 249 patients (3.8%), respectively (hazard ratio, 0.91; 95% CI, 0.76 to 1.09).
- CV death or worsening HF · Results, paragraph 1; Table 2
Death from cardiovascular causes or hospitalization or urgent visit for heart failure ... occurred in 512 patients (7.8%) in the tirzepatide group and 557 (8.5%) ... (hazard ratio, 0.91; 95% CI, 0.81 to 1.03)
- Expanded MACE (MACE + revasc.) · Table 2, key secondary end points
| Death from cardiovascular causes, myocardial infarction, stroke, or coronary revascularization — no. (%) | 1089 (16.5) | 1217 (18.5) | 0.88 (0.81 to 0.96) |
SUMMIT tirzepatide 5–15 mg vs placebo · HFpEF + obesity · n = 731 · 2024 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| Cardiovascular death Adjudicated death from cardiovascular causes (excludes 2 tirzepatide deaths of undetermined cause, which are counted as CV deaths in the composite) | 1.58 | 0.52–4.83 | 8 vs 5 | verified |
| All-cause death Death from any cause | 1.25 | 0.63–2.45 | 19 vs 15 | verified |
| Hospitalisation for heart failure Adjudicated worsening heart-failure event resulting in hospitalization (first event) | 0.44 | 0.22–0.87 | 12 vs 26 | verified |
| CV death or worsening HF primary Adjudicated CV death (including undetermined cause) or worsening heart-failure event (hospitalization, IV therapy in urgent care, or intensified oral diuretics) | 0.62 | 0.41–0.95 | 36 vs 56 | verified |
Verbatim quotes (4)
- Cardiovascular death · Abstract; Table 2
adjudicated death from cardiovascular causes occurred in 8 patients (2.2%) and 5 patients (1.4%), respectively (hazard ratio, 1.58; 95% CI, 0.52 to 4.83)
- All-cause death · Results, Primary End Points; Table 2
Death from any cause occurred in 19 patients in tirzepatide group and in 15 patients in the placebo group (hazard ratio, 1.25; 95% CI, 0.63 to 2.45)
- Hospitalisation for heart failure · Table 2
Adjudicated worsening heart-failure event resulting in hospitalization — no. (%) 12 (3.3) 1.8 26 (7.1) 3.9 0.44 (0.22 to 0.87)
- CV death or worsening HF · Results, Primary End Points; Table 2; Figure 1
occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (...hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P = 0.026)
Other indications
SUMMIT Tirzepatide · HFpEF + obesity · 104 weeks · n = 731 seed
CV death or worsening HF HR 0.62; KCCQ-CSS +6.9 points
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Cardiovascular death or worsening heart-failure event (time to first event) week 104 | +9.9 | +15.3 | +0.6 (+0.4 to +0.9) hazard ratio | verified |
| KCCQ clinical summary score, change from baseline week 52 | +19.5 | +12.7 | +6.9 (+3.3 to +10.6) points (0-100) | verified |
Verbatim quotes (2)
- Cardiovascular death or worsening heart-failure event (time to first event)
Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P = 0.026)
- KCCQ clinical summary score, change from baseline
the mean (±SD) change in the KCCQ-CSS was 19.5±1.2 in the tirzepatide group as compared with 12.7±1.3 in the placebo group (between-group difference, 6.9; 95% CI, 3.3 to 10.6; P<0.001)
SURMOUNT-OSA Tirzepatide · Obstructive sleep apnoea + obesity · 52 weeks · n = 469 seed
AHI −25.3 vs −5.3 events/h (trial 1), −29.3 vs −5.5 (trial 2, on PAP); FDA label Dec 2024
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Apnea-hypopnea index, change from baseline trial 1 week 52 | −25.3 | −5.3 | −20.0 (−25.8 to −14.2) events/h | verified |
| Apnea-hypopnea index, change from baseline trial 2 week 52 | −29.3 | −5.5 | −23.8 (−29.6 to −17.9) events/h | verified |
Verbatim quotes (2)
- Apnea-hypopnea index, change from baseline
In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2)
- Apnea-hypopnea index, change from baseline
In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9)
SYNERGY-NASH Tirzepatide · MASH F2–F3 · 52 weeks · n = 190 seed
MASH resolution without worsening fibrosis 44–62 % vs 10 %
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| MASH resolution without worsening of fibrosis - tirzepatide 10 mg 10 mg week 52 | +56.0 | +10.0 | +46.0 (+29.0 to +62.0) percentage points | verified |
| MASH resolution without worsening of fibrosis - tirzepatide 15 mg 15 mg week 52 | +62.0 | +10.0 | +53.0 (+37.0 to +69.0) percentage points | verified |
| MASH resolution without worsening of fibrosis - tirzepatide 5 mg 5 mg week 52 | +44.0 | +10.0 | +34.0 (+17.0 to +50.0) percentage points | verified |
Verbatim quotes (3)
- MASH resolution without worsening of fibrosis - tirzepatide 10 mg
56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62)
- MASH resolution without worsening of fibrosis - tirzepatide 15 mg
62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69)
- MASH resolution without worsening of fibrosis - tirzepatide 5 mg
44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50)
Ongoing outcome trials
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| SURMOUNT-MMO | Tirzepatide | Obesity, morbidity and mortality Obesity without diabetes (T2D excluded), established CVD or risk factors | Composite of death and CV events | 15374 | active not recruiting | 2027-10 | NCT05556512 |
Registered trials (66)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07265752 Tirzepatide for the Treatment of Cannabis Use Disorder | Addiction | Phase 2 | not yet recruiting | 2027-03 → 2028-06 | 6 | not yet recruiting | NCT07265752 |
| TirBaS Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | Obesity | Phase 3 | not yet recruiting | 2027-01 → 2028-12 | 70 | not yet recruiting | NCT07829198 |
| CUD Trial of Tirzepatide for the Treatment of Cannabis Use Disorder | Addiction | Phase 2 | not yet recruiting | 2026-11 → 2028-03 | 100 | not yet recruiting | NCT07468552 |
| T-STEM Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder | Addiction | Phase 2 | recruiting | 2026-10 → 2031-07 | 228 | recruiting | NCT07825857 |
| TIRZE-PAP Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea | Sleep apnoea | Phase 3 | not yet recruiting | 2026-10 → 2028-12 | 256 | not yet recruiting | NCT07846865 |
| NCT07906041 Tirzepatide and Organ-specific Biological Aging | Other | Phase 2 | enrolling by invitation | 2026-10 → 2028-04 | 22 | enrolling by invitation | NCT07906041 |
| TOPAZ Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial | Neurology | Phase 3 | recruiting | 2026-09 → 2028-05 | 726 | recruiting | NCT07734792 |
| NCT07734870 Tirzepatide for Treatment of CCCA | Other | Phase 2 | recruiting | 2026-09 → 2028-05 | 20 | recruiting | NCT07734870 |
| ADVANCE-SURMOUNT-KIDS Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) | Obesity | Phase 3 | recruiting | 2026-09 → 2029-12 | 150 | recruiting | NCT07817875 |
| EXER-MED The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | Obesity | Phase 3 | not yet recruiting | 2026-08 → 2026-12 | 24 | not yet recruiting | NCT07298915 |
| NCT07671248 Tirzepatide in the Treatment of Cannabis Use Disorder | Addiction | Phase 3 | not yet recruiting | 2026-08 → 2028-07 | 15 | not yet recruiting | NCT07671248 |
| CLARA Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial | Other | Phase 2 | not yet recruiting | 2026-08 → 2028-03 | 168 | not yet recruiting | NCT07676331 |
| TRI-MR An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder | Addiction | Phase 2 | active not recruiting | 2026-08 → 2030-02 | 45 | active not recruiting | NCT07693608 |
| NCT07573163 Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion | Other | Phase 2 | recruiting | 2026-07 → 2028-07 | 34 | recruiting | NCT07573163 |
| DUAL-HFrEF Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | HFpEF | Phase 3 | not yet recruiting | 2026-07 → 2027-06 | 60 | not yet recruiting | NCT07738276 |
| NCT07046819 Tirzepatide in MetALD | Other | Phase 2 | recruiting | 2026-06 → 2027-07 | 120 | recruiting | NCT07046819 |
| NCT07602699 Multi-Site Trial of Tirzepatide for Smoking Cessation | Addiction | Phase 2 | recruiting | 2026-06 → 2028-03 | 300 | recruiting | NCT07602699 |
| TREAT-EC Tirzepatide in the Treatment of Endometrial Cancer | Other | Phase 2 | not yet recruiting | 2026-06 → 2028-01 | 30 | not yet recruiting | NCT07605247 |
| NCT07527910 A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | MASH | Phase 2 | recruiting | 2026-05 → 2030-03 | 204 | recruiting | NCT07527910 |
| NCT07220473 Tirzepatide to Slow Biological Aging | Other | Phase 2 | recruiting | 2026-02 → 2027-11 | 90 | recruiting | NCT07220473 |
| SURMOUNT-1 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Obesity | Phase 3 | recruiting | 2026-02 → 2027-02 | 2539 | recruiting | NCT07481747 |
| TAB Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Addiction | Phase 2 | recruiting | 2026-01 → 2027-09 | 310 | recruiting | NCT06651177 |
| OOB Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) | Alzheimer's | Phase 2 | not yet recruiting | 2026-01 → 2027-05 | 46 | not yet recruiting | NCT07292519 |
| NCT07834398 Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes | Obesity | Phase 3 | completed | 2025-11 → 2026-04 | 150 | Completed; results not in the atlas yet | NCT07834398 |
| NCT06994338 Tirzepatide for Alcohol Use Disorder | Addiction | Phase 2 | recruiting | 2025-10 → 2026-08 | 42 | recruiting | NCT06994338 |
| LOCITT The Long COVID Treatment Trial | Other | Phase 2 | active not recruiting | 2025-10 → 2026-12 | 1000 | active not recruiting | NCT07128082 |
| STREAM Study of Tirzepatide for Recovery and Alcohol Use Management | Addiction | Phase 2 | recruiting | 2025-09 → 2027-03 | 20 | recruiting | NCT06727331 |
| LIBERATE Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder | Addiction | Phase 2 | recruiting | 2025-09 → 2027-12 | 105 | recruiting | NCT06847399 |
| TILT-2024 Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024 | Other | Phase 2 | recruiting | 2025-09 → 2029-09 | 32 | recruiting | NCT07091734 |
| COMMIT-UC Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Obesity | Phase 3 | recruiting | 2025-06 → 2028-04 | 350 | recruiting | NCT06937086 |
| COMMIT-CD Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Obesity | Phase 3 | recruiting | 2025-06 → 2028-05 | 290 | recruiting | NCT06937099 |
| DUALPSYCHIATRY Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder | Addiction | Phase 2 | recruiting | 2025-05 → 2028-08 | 108 | recruiting | NCT06939088 |
| NCT06976853 Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | Other | Phase 2 | recruiting | 2025-05 → 2028-05 | 60 | recruiting | NCT06976853 |
| NCT06745128 Tirzepatide for Obesity and Meth Use Disorder | Addiction | Phase 2 | completed | 2025-02 → 2026-02 | 35 | Completed; results not in the atlas yet | NCT06745128 |
| NCT06918405 Efficacy and Safety of Tirzepatide for Weight Management | Obesity | Phase 3 | active not recruiting | 2025-01 → 2026-06 | 440 | active not recruiting | NCT06918405 |
| NCT06246799 Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes | T2D | Phase 3 | recruiting | 2024-11 → 2029-04 | 256 | recruiting | NCT06246799 |
| GRABS-0 GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | Obesity | Phase 3 | active not recruiting | 2024-10 → 2026-10 | 30 | active not recruiting | NCT06162715 |
| TOGETHER-PsO Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Obesity | Phase 3 | completed | 2024-09 → 2026-01 | 281 | Completed; results not in the atlas yet | NCT06588283 |
| TOGETHER-PsA Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Obesity | Phase 3 | completed | 2024-09 → 2025-11 | 279 | Completed; results not in the atlas yet | NCT06588296 |
| SURMOUNT-ADOLESCENTS-2 A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Obesity | Phase 3 | recruiting | 2024-06 → 2027-10 | 300 | recruiting | NCT06439277 |
| NCT05659368 Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1 | Other | Phase 2 | unknown | 2024-01 → 2024-10 | 10 | unknown | NCT05659368 |
| SURMOUNT-ADOLESCENTS A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity | Phase 3 | active not recruiting | 2023-10 → 2026-06 | 160 | active not recruiting | NCT06075667 |
| SURMOUNT-MAINTAIN A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity | Phase 3 | completed | 2023-09 → 2026-01 | 441 | Completed; results not in the atlas yet | NCT06047548 |
| SURPASS-CN-MONO A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) | T2D | Phase 3 | completed | 2023-08 → 2024-10 | 206 | Completed; results not in the atlas yet | NCT05963022 |
| TREASURE-CKD A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | CKD | Phase 2 | completed | 2023-02 → 2026-07 | 134 | Completed; results not in the atlas yet | NCT05536804 |
| SURPASS-CN-INS A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes | T2D | Phase 3 | completed | 2023-02 → 2024-07 | 257 | Completed; results not in the atlas yet | NCT05691712 |
| SURMOUNT-MMO A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | CV outcomes | Phase 3 | active not recruiting | 2022-10 → 2027-10 | 15374 | NCT05556512 | |
| SURMOUNT-OSA Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Sleep apnoea | Phase 3 | completed | 2022-06 → 2024-03 | 469 | AHI −25.3 vs −5.3 events/h | NCT05412004 |
| SURPASS-PEDS A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both | T2D | Phase 3 | completed | 2022-04 → 2024-07 | 99 | Completed; results not in the atlas yet | NCT05260021 |
| SURMOUNT-CN A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) | Obesity | Phase 3 | completed | 2021-09 → 2022-12 | 210 | Completed; results not in the atlas yet | NCT05024032 |
| SURMOUNT-J A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease | Obesity | Phase 3 | completed | 2021-05 → 2023-06 | 267 | Completed; results not in the atlas yet | NCT04844918 |
| SUMMIT A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | HFpEF | Phase 3 | completed | 2021-04 → 2024-07 | 731 | CV death or worsening HF HR 0.62 (0.41–0.95) | NCT04847557 |
| SURMOUNT-2 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | Obesity | Phase 3 | completed | 2021-03 → 2023-03 | 938 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT04657003 |
| SURMOUNT-3 A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program | Obesity | Phase 3 | completed | 2021-03 → 2023-04 | 579 | Completed; results not in the atlas yet | NCT04657016 |
| SURMOUNT-4 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss | Obesity | Phase 3 | completed | 2021-03 → 2023-04 | 783 | Completed; results not in the atlas yet | NCT04660643 |
| SURPASS-6 A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin | T2D | Phase 3 | completed | 2020-10 → 2022-10 | 1428 | Completed; results not in the atlas yet | NCT04537923 |
| SURPASS-CVOT A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | CV outcomes | Phase 3 | completed | 2020-05 → 2025-06 | 13299 | MACE HR 0.92 (0.83–1.01) vs dulaglutide: non-inferior | NCT04255433 |
| SURPASS-AP-Combo A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) | T2D | Phase 3 | completed | 2019-12 → 2021-11 | 917 | Completed; results not in the atlas yet | NCT04093752 |
| SURMOUNT-1 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | Obesity | Phase 3 | completed | 2019-12 → 2022-04 | 2539 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT04184622 |
| SYNERGY-NASH A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | MASH | Phase 2 | completed | 2019-11 → 2023-12 | 190 | MASH resolution 44–62 % vs 10 % (phase 2) | NCT04166773 |
| SURPASS-5 A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin | T2D | Phase 3 | completed | 2019-08 → 2020-12 | 475 | Completed; results not in the atlas yet | NCT04039503 |
| SURPASS-1 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | T2D | Phase 3 | completed | 2019-06 → 2020-10 | 478 | Completed; results not in the atlas yet | NCT03954834 |
| SURPASS J-mono A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes | T2D | Phase 3 | completed | 2019-05 → 2021-03 | 636 | Completed; results not in the atlas yet | NCT03861052 |
| SURPASS-3 A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | T2D | Phase 3 | completed | 2019-04 → 2020-12 | 1444 | Completed; results not in the atlas yet | NCT03882970 |
| SURPASS J-combo A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | T2D | Phase 3 | completed | 2019-03 → 2021-01 | 443 | Completed; results not in the atlas yet | NCT03861039 |
| SURPASS-4 A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | T2D | Phase 3 | completed | 2018-11 → 2021-01 | 2002 | Completed; results not in the atlas yet | NCT03730662 |
Primary sources
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
- Eli Lilly and Company. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) (SURMOUNT-1). ClinicalTrials.gov identifier NCT04184622. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04184622
- Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. PMID: 37385275.
- Eli Lilly and Company. Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2) (SURMOUNT-2). ClinicalTrials.gov identifier NCT04657003. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04657003
- Eli Lilly and Company. A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5). ClinicalTrials.gov identifier NCT05822830. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05822830
- Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. PMID: 40353578.
- Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30. Available from: https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html
- Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420. PMID: 41406444.
- Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT) (SURPASS-CVOT). ClinicalTrials.gov identifier NCT04255433. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04255433
- SURPASS-CVOT: clinically relevant trial insights [session]. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Available from: https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/
- Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. PMID: 39555826.
- Eli Lilly and Company. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT). ClinicalTrials.gov identifier NCT04847557. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04847557
- Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PMID: 38912654.
- Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. PMID: 38856224.
- Eli Lilly and Company. A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO). ClinicalTrials.gov identifier NCT05556512. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05556512
How to cite this page
Cite the primary publication for any single result; every value above links to it.